MIF and early-onset autosomal dominant Alzheimer disease: On the other hand, in-vitro, in-vivo, and ex-vivo preclinical data, as well as data from Alzheimer' s disease patients have shown that MIF is increased during the course of the disease and that therapeutic targeting of MIF could beneficial effects on the Alzheimer' s disease course [38].